nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—SLC22A3—prostate cancer	0.104	0.275	CbGaD
Imipramine—CYP2C18—prostate cancer	0.0918	0.242	CbGaD
Imipramine—SLC22A1—prostate cancer	0.0749	0.197	CbGaD
Imipramine—CYP2E1—prostate cancer	0.0415	0.109	CbGaD
Imipramine—CYP2C19—prostate cancer	0.0411	0.108	CbGaD
Imipramine—ORM1—Abiraterone—prostate cancer	0.0376	0.109	CbGbCtD
Imipramine—CYP3A4—prostate cancer	0.0262	0.0689	CbGaD
Imipramine—SLC22A3—Estradiol—prostate cancer	0.0218	0.0632	CbGbCtD
Imipramine—SLC22A2—Estradiol—prostate cancer	0.0129	0.0374	CbGbCtD
Imipramine—CYP2C19—Bicalutamide—prostate cancer	0.0124	0.0359	CbGbCtD
Imipramine—CYP2C19—Nilutamide—prostate cancer	0.0124	0.0359	CbGbCtD
Imipramine—CYP2E1—Estrone—prostate cancer	0.0118	0.0343	CbGbCtD
Imipramine—CYP2B6—Estrone—prostate cancer	0.0117	0.0338	CbGbCtD
Imipramine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0114	0.033	CbGbCtD
Imipramine—SLC22A1—Estradiol—prostate cancer	0.0112	0.0325	CbGbCtD
Imipramine—CYP2B6—Ethinyl Estradiol—prostate cancer	0.0104	0.0302	CbGbCtD
Imipramine—CYP2C19—Flutamide—prostate cancer	0.0103	0.0297	CbGbCtD
Imipramine—CYP1A2—Flutamide—prostate cancer	0.00946	0.0274	CbGbCtD
Imipramine—CYP2D6—Bicalutamide—prostate cancer	0.00941	0.0273	CbGbCtD
Imipramine—ABCB1—Estramustine—prostate cancer	0.00929	0.0269	CbGbCtD
Imipramine—ADRA1B—vas deferens—prostate cancer	0.00849	0.182	CbGeAlD
Imipramine—CYP2D6—Abiraterone—prostate cancer	0.0078	0.0226	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Estradiol—prostate cancer	0.00704	0.0204	CbGbCtD
Imipramine—CYP3A7—Estradiol—prostate cancer	0.00704	0.0204	CbGbCtD
Imipramine—CYP2E1—Mitoxantrone—prostate cancer	0.00704	0.0204	CbGbCtD
Imipramine—CYP1A2—Estrone—prostate cancer	0.00684	0.0198	CbGbCtD
Imipramine—ABCB1—Cabazitaxel—prostate cancer	0.00612	0.0177	CbGbCtD
Imipramine—CYP3A4—Bicalutamide—prostate cancer	0.00598	0.0174	CbGbCtD
Imipramine—ABCB1—Estrone—prostate cancer	0.00598	0.0173	CbGbCtD
Imipramine—CYP3A4—Estramustine—prostate cancer	0.00556	0.0161	CbGbCtD
Imipramine—ABCB1—Ethinyl Estradiol—prostate cancer	0.00533	0.0155	CbGbCtD
Imipramine—CYP3A4—Abiraterone—prostate cancer	0.00496	0.0144	CbGbCtD
Imipramine—CYP3A4—Flutamide—prostate cancer	0.00496	0.0144	CbGbCtD
Imipramine—HTR7—vas deferens—prostate cancer	0.00495	0.106	CbGeAlD
Imipramine—CYP1A2—Conjugated Estrogens—prostate cancer	0.00448	0.013	CbGbCtD
Imipramine—CYP2E1—Etoposide—prostate cancer	0.00444	0.0129	CbGbCtD
Imipramine—CYP2C19—Estradiol—prostate cancer	0.00426	0.0123	CbGbCtD
Imipramine—CYP3A7—Docetaxel—prostate cancer	0.00421	0.0122	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Docetaxel—prostate cancer	0.00421	0.0122	CbGbCtD
Imipramine—CHRM3—ureter—prostate cancer	0.00398	0.0854	CbGeAlD
Imipramine—CYP1A2—Estradiol—prostate cancer	0.00393	0.0114	CbGbCtD
Imipramine—ABCB1—Conjugated Estrogens—prostate cancer	0.00391	0.0113	CbGbCtD
Imipramine—CYP3A4—Cabazitaxel—prostate cancer	0.00367	0.0106	CbGbCtD
Imipramine—CYP2C19—Prednisone—prostate cancer	0.00366	0.0106	CbGbCtD
Imipramine—CYP3A4—Estrone—prostate cancer	0.00358	0.0104	CbGbCtD
Imipramine—ABCB1—Mitoxantrone—prostate cancer	0.00356	0.0103	CbGbCtD
Imipramine—ABCB1—Estradiol—prostate cancer	0.00344	0.00996	CbGbCtD
Imipramine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0032	0.00926	CbGbCtD
Imipramine—CYP2B6—Doxorubicin—prostate cancer	0.00299	0.00866	CbGbCtD
Imipramine—ABCB1—Prednisone—prostate cancer	0.00296	0.00857	CbGbCtD
Imipramine—CYP1A2—Etoposide—prostate cancer	0.00257	0.00744	CbGbCtD
Imipramine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00235	0.0068	CbGbCtD
Imipramine—ABCB1—Etoposide—prostate cancer	0.00224	0.00651	CbGbCtD
Imipramine—CYP3A4—Mitoxantrone—prostate cancer	0.00213	0.00618	CbGbCtD
Imipramine—CYP3A4—Estradiol—prostate cancer	0.00206	0.00597	CbGbCtD
Imipramine—ABCB1—Docetaxel—prostate cancer	0.00205	0.00595	CbGbCtD
Imipramine—CYP3A4—Prednisone—prostate cancer	0.00177	0.00513	CbGbCtD
Imipramine—ABCB1—Doxorubicin—prostate cancer	0.00153	0.00444	CbGbCtD
Imipramine—CYP2D6—Doxorubicin—prostate cancer	0.00144	0.00418	CbGbCtD
Imipramine—CYP3A4—Etoposide—prostate cancer	0.00134	0.0039	CbGbCtD
Imipramine—CYP3A4—Docetaxel—prostate cancer	0.00123	0.00357	CbGbCtD
Imipramine—CYP2C19—urine—prostate cancer	0.0012	0.0258	CbGeAlD
Imipramine—KCND3—prostate gland—prostate cancer	0.00111	0.0239	CbGeAlD
Imipramine—CYP1A2—urine—prostate cancer	0.000981	0.0211	CbGeAlD
Imipramine—CYP3A4—Doxorubicin—prostate cancer	0.000917	0.00266	CbGbCtD
Imipramine—CYP2E1—urine—prostate cancer	0.000883	0.019	CbGeAlD
Imipramine—HTR2A—urine—prostate cancer	0.000767	0.0165	CbGeAlD
Imipramine—ADRA1D—prostate gland—prostate cancer	0.000742	0.0159	CbGeAlD
Imipramine—CYP3A4—urine—prostate cancer	0.00071	0.0152	CbGeAlD
Imipramine—CYP2D6—urine—prostate cancer	0.000699	0.015	CbGeAlD
Imipramine—ORM1—prostate gland—prostate cancer	0.000611	0.0131	CbGeAlD
Imipramine—CHRM5—epithelium—prostate cancer	0.00061	0.0131	CbGeAlD
Imipramine—SLC22A4—prostate gland—prostate cancer	0.000588	0.0126	CbGeAlD
Imipramine—CHRM2—prostate gland—prostate cancer	0.00057	0.0122	CbGeAlD
Imipramine—KCND2—testis—prostate cancer	0.000563	0.0121	CbGeAlD
Imipramine—ADRA1D—epithelium—prostate cancer	0.000545	0.0117	CbGeAlD
Imipramine—SLC22A2—renal system—prostate cancer	0.00054	0.0116	CbGeAlD
Imipramine—SLC22A3—prostate gland—prostate cancer	0.000535	0.0115	CbGeAlD
Imipramine—CHRM1—prostate gland—prostate cancer	0.000518	0.0111	CbGeAlD
Imipramine—ADRA1B—renal system—prostate cancer	0.000517	0.0111	CbGeAlD
Imipramine—SLC22A4—seminal vesicle—prostate cancer	0.000497	0.0107	CbGeAlD
Imipramine—ADRA1D—urethra—prostate cancer	0.000497	0.0107	CbGeAlD
Imipramine—KCND3—testis—prostate cancer	0.000491	0.0105	CbGeAlD
Imipramine—CHRM4—testis—prostate cancer	0.000468	0.01	CbGeAlD
Imipramine—CHRM3—prostate gland—prostate cancer	0.000464	0.00996	CbGeAlD
Imipramine—SLC22A3—seminal vesicle—prostate cancer	0.000452	0.00971	CbGeAlD
Imipramine—ADRA1A—prostate gland—prostate cancer	0.000426	0.00915	CbGeAlD
Imipramine—KCNH2—prostate gland—prostate cancer	0.000411	0.00883	CbGeAlD
Imipramine—SLC22A4—renal system—prostate cancer	0.0004	0.0086	CbGeAlD
Imipramine—SLC22A1—renal system—prostate cancer	0.000381	0.00819	CbGeAlD
Imipramine—SLC22A3—renal system—prostate cancer	0.000364	0.00782	CbGeAlD
Imipramine—SLC22A3—urethra—prostate cancer	0.000358	0.00769	CbGeAlD
Imipramine—KCND3—lymph node—prostate cancer	0.000356	0.00764	CbGeAlD
Imipramine—KCNH2—seminal vesicle—prostate cancer	0.000348	0.00747	CbGeAlD
Imipramine—HRH1—prostate gland—prostate cancer	0.00033	0.00708	CbGeAlD
Imipramine—HTR7—epithelium—prostate cancer	0.000325	0.00697	CbGeAlD
Imipramine—CYP2E1—prostate gland—prostate cancer	0.000317	0.0068	CbGeAlD
Imipramine—CHRM3—renal system—prostate cancer	0.000316	0.00679	CbGeAlD
Imipramine—HTR1A—renal system—prostate cancer	0.000315	0.00676	CbGeAlD
Imipramine—ORM1—bone marrow—prostate cancer	0.000315	0.00676	CbGeAlD
Imipramine—ADRA1A—epithelium—prostate cancer	0.000313	0.00672	CbGeAlD
Imipramine—CHRM3—urethra—prostate cancer	0.000311	0.00667	CbGeAlD
Imipramine—SLC22A4—bone marrow—prostate cancer	0.000303	0.0065	CbGeAlD
Imipramine—HTR7—renal system—prostate cancer	0.000301	0.00646	CbGeAlD
Imipramine—ADRA1A—renal system—prostate cancer	0.00029	0.00623	CbGeAlD
Imipramine—KCNH2—renal system—prostate cancer	0.00028	0.00602	CbGeAlD
Imipramine—KCNH2—urethra—prostate cancer	0.000275	0.00591	CbGeAlD
Imipramine—CYP2E1—seminal vesicle—prostate cancer	0.000268	0.00575	CbGeAlD
Imipramine—SLC6A3—testis—prostate cancer	0.00025	0.00537	CbGeAlD
Imipramine—HRH1—epithelium—prostate cancer	0.000242	0.0052	CbGeAlD
Imipramine—CYP1A2—renal system—prostate cancer	0.00024	0.00515	CbGeAlD
Imipramine—Dimetacrine—ACHE—prostate cancer	0.000238	0.0845	CrCbGaD
Imipramine—SLC22A3—testis—prostate cancer	0.000236	0.00506	CbGeAlD
Imipramine—CYP2B6—renal system—prostate cancer	0.00023	0.00494	CbGeAlD
Imipramine—Carbamazepine—RALBP1—prostate cancer	0.000229	0.0814	CrCbGaD
Imipramine—HRH1—urethra—prostate cancer	0.000221	0.00474	CbGeAlD
Imipramine—CYP2E1—renal system—prostate cancer	0.000216	0.00464	CbGeAlD
Imipramine—CYP2E1—urethra—prostate cancer	0.000212	0.00455	CbGeAlD
Imipramine—KCNH2—bone marrow—prostate cancer	0.000212	0.00455	CbGeAlD
Imipramine—CHRM3—testis—prostate cancer	0.000204	0.00439	CbGeAlD
Imipramine—HTR2A—epithelium—prostate cancer	0.000202	0.00434	CbGeAlD
Imipramine—SLC6A2—testis—prostate cancer	0.000202	0.00433	CbGeAlD
Imipramine—ORM1—lymph node—prostate cancer	0.000195	0.00419	CbGeAlD
Imipramine—HTR7—testis—prostate cancer	0.000195	0.00418	CbGeAlD
Imipramine—HTR2A—renal system—prostate cancer	0.000188	0.00403	CbGeAlD
Imipramine—SLC22A4—lymph node—prostate cancer	0.000188	0.00403	CbGeAlD
Imipramine—DRD2—testis—prostate cancer	0.000184	0.00395	CbGeAlD
Imipramine—KCNH2—testis—prostate cancer	0.000181	0.00389	CbGeAlD
Imipramine—ABCB1—prostate gland—prostate cancer	0.00018	0.00387	CbGeAlD
Imipramine—CYP3A4—renal system—prostate cancer	0.000174	0.00373	CbGeAlD
Imipramine—CYP2D6—renal system—prostate cancer	0.000171	0.00367	CbGeAlD
Imipramine—SLC22A3—lymph node—prostate cancer	0.000171	0.00367	CbGeAlD
Imipramine—ABCB1—seminal vesicle—prostate cancer	0.000153	0.00328	CbGeAlD
Imipramine—CYP2B6—testis—prostate cancer	0.000149	0.00319	CbGeAlD
Imipramine—SLC6A2—lymph node—prostate cancer	0.000146	0.00314	CbGeAlD
Imipramine—HRH1—testis—prostate cancer	0.000145	0.00312	CbGeAlD
Imipramine—CYP2E1—testis—prostate cancer	0.00014	0.003	CbGeAlD
Imipramine—Benazepril—MTHFR—prostate cancer	0.000135	0.0479	CrCbGaD
Imipramine—ABCB1—epithelium—prostate cancer	0.000133	0.00285	CbGeAlD
Imipramine—KCNH2—lymph node—prostate cancer	0.000131	0.00282	CbGeAlD
Imipramine—ABCB1—renal system—prostate cancer	0.000123	0.00264	CbGeAlD
Imipramine—HTR2A—testis—prostate cancer	0.000121	0.0026	CbGeAlD
Imipramine—ABCB1—urethra—prostate cancer	0.000121	0.00259	CbGeAlD
Imipramine—CYP2D6—testis—prostate cancer	0.000111	0.00237	CbGeAlD
Imipramine—Benazepril—ACE—prostate cancer	0.00011	0.039	CrCbGaD
Imipramine—HRH1—lymph node—prostate cancer	0.000105	0.00226	CbGeAlD
Imipramine—ABCB1—bone marrow—prostate cancer	9.3e-05	0.002	CbGeAlD
Imipramine—Oxcarbazepine—CYP3A5—prostate cancer	9.07e-05	0.0322	CrCbGaD
Imipramine—Acepromazine—SLC22A1—prostate cancer	8.49e-05	0.0302	CrCbGaD
Imipramine—Thioproperazine—SLC22A1—prostate cancer	8.3e-05	0.0295	CrCbGaD
Imipramine—Pipotiazine—SLC22A1—prostate cancer	8.17e-05	0.029	CrCbGaD
Imipramine—ABCB1—testis—prostate cancer	7.95e-05	0.00171	CbGeAlD
Imipramine—Desipramine—SLC22A3—prostate cancer	7.24e-05	0.0257	CrCbGaD
Imipramine—Diphenhydramine—CYP2C18—prostate cancer	7.14e-05	0.0254	CrCbGaD
Imipramine—Clomipramine—GSTP1—prostate cancer	6.98e-05	0.0248	CrCbGaD
Imipramine—Desipramine—CYP2C18—prostate cancer	6.36e-05	0.0226	CrCbGaD
Imipramine—Carbamazepine—CYP3A5—prostate cancer	6.18e-05	0.0219	CrCbGaD
Imipramine—Oxcarbazepine—CYP2C19—prostate cancer	6.17e-05	0.0219	CrCbGaD
Imipramine—Diphenhydramine—SLC22A1—prostate cancer	5.83e-05	0.0207	CrCbGaD
Imipramine—ABCB1—lymph node—prostate cancer	5.76e-05	0.00124	CbGeAlD
Imipramine—Desipramine—SLC22A1—prostate cancer	5.19e-05	0.0184	CrCbGaD
Imipramine—Olopatadine—CYP3A4—prostate cancer	5.11e-05	0.0181	CrCbGaD
Imipramine—Nortriptyline—CYP3A5—prostate cancer	5.09e-05	0.0181	CrCbGaD
Imipramine—Alimemazine—CYP3A4—prostate cancer	4.66e-05	0.0165	CrCbGaD
Imipramine—Pipotiazine—CYP2C19—prostate cancer	4.49e-05	0.0159	CrCbGaD
Imipramine—Chlorpromazine—SLC22A1—prostate cancer	4.43e-05	0.0157	CrCbGaD
Imipramine—Cyclobenzaprine—CYP3A4—prostate cancer	4.29e-05	0.0152	CrCbGaD
Imipramine—Epinastine—CYP3A4—prostate cancer	4.26e-05	0.0151	CrCbGaD
Imipramine—Carbamazepine—CYP2C19—prostate cancer	4.21e-05	0.0149	CrCbGaD
Imipramine—Desipramine—CYP2A6—prostate cancer	4.06e-05	0.0144	CrCbGaD
Imipramine—Mequitazine—CYP3A4—prostate cancer	4.01e-05	0.0142	CrCbGaD
Imipramine—Oxcarbazepine—CYP3A4—prostate cancer	3.93e-05	0.0139	CrCbGaD
Imipramine—Infestation—Doxorubicin—prostate cancer	3.67e-05	0.000287	CcSEcCtD
Imipramine—Drowsiness—Doxorubicin—prostate cancer	3.67e-05	0.000287	CcSEcCtD
Imipramine—Dermatitis—Estradiol—prostate cancer	3.67e-05	0.000287	CcSEcCtD
Imipramine—Confusional state—Capecitabine—prostate cancer	3.66e-05	0.000286	CcSEcCtD
Imipramine—Tachycardia—Docetaxel—prostate cancer	3.66e-05	0.000286	CcSEcCtD
Imipramine—Headache—Estradiol—prostate cancer	3.65e-05	0.000285	CcSEcCtD
Imipramine—Skin disorder—Docetaxel—prostate cancer	3.65e-05	0.000285	CcSEcCtD
Imipramine—Agitation—Prednisone—prostate cancer	3.64e-05	0.000285	CcSEcCtD
Imipramine—Oedema—Capecitabine—prostate cancer	3.63e-05	0.000284	CcSEcCtD
Imipramine—Infection—Capecitabine—prostate cancer	3.61e-05	0.000282	CcSEcCtD
Imipramine—Neuropathy peripheral—Doxorubicin—prostate cancer	3.6e-05	0.000281	CcSEcCtD
Imipramine—Urticaria—Etoposide—prostate cancer	3.59e-05	0.00028	CcSEcCtD
Imipramine—Jaundice—Doxorubicin—prostate cancer	3.58e-05	0.000279	CcSEcCtD
Imipramine—Stomatitis—Doxorubicin—prostate cancer	3.58e-05	0.000279	CcSEcCtD
Imipramine—Anorexia—Docetaxel—prostate cancer	3.58e-05	0.000279	CcSEcCtD
Imipramine—Malaise—Prednisone—prostate cancer	3.58e-05	0.000279	CcSEcCtD
Imipramine—Shock—Capecitabine—prostate cancer	3.57e-05	0.000279	CcSEcCtD
Imipramine—Body temperature increased—Etoposide—prostate cancer	3.57e-05	0.000279	CcSEcCtD
Imipramine—Abdominal pain—Etoposide—prostate cancer	3.57e-05	0.000279	CcSEcCtD
Imipramine—Nervous system disorder—Capecitabine—prostate cancer	3.56e-05	0.000278	CcSEcCtD
Imipramine—Hepatitis—Epirubicin—prostate cancer	3.56e-05	0.000278	CcSEcCtD
Imipramine—Thrombocytopenia—Capecitabine—prostate cancer	3.56e-05	0.000278	CcSEcCtD
Imipramine—Syncope—Prednisone—prostate cancer	3.56e-05	0.000278	CcSEcCtD
Imipramine—Tachycardia—Capecitabine—prostate cancer	3.55e-05	0.000277	CcSEcCtD
Imipramine—Clomipramine—CYP2C19—prostate cancer	3.55e-05	0.0126	CrCbGaD
Imipramine—Hypoaesthesia—Epirubicin—prostate cancer	3.54e-05	0.000277	CcSEcCtD
Imipramine—Amitriptyline—CYP3A5—prostate cancer	3.53e-05	0.0125	CrCbGaD
Imipramine—Skin disorder—Capecitabine—prostate cancer	3.53e-05	0.000276	CcSEcCtD
Imipramine—Urinary tract disorder—Epirubicin—prostate cancer	3.52e-05	0.000275	CcSEcCtD
Imipramine—Hyperhidrosis—Capecitabine—prostate cancer	3.51e-05	0.000274	CcSEcCtD
Imipramine—Nortriptyline—CYP2E1—prostate cancer	3.5e-05	0.0124	CrCbGaD
Imipramine—Urethral disorder—Epirubicin—prostate cancer	3.49e-05	0.000273	CcSEcCtD
Imipramine—Loss of consciousness—Prednisone—prostate cancer	3.49e-05	0.000272	CcSEcCtD
Imipramine—Hepatobiliary disease—Doxorubicin—prostate cancer	3.47e-05	0.000271	CcSEcCtD
Imipramine—Nortriptyline—CYP2C19—prostate cancer	3.47e-05	0.0123	CrCbGaD
Imipramine—Anorexia—Capecitabine—prostate cancer	3.46e-05	0.00027	CcSEcCtD
Imipramine—Nausea—Estradiol—prostate cancer	3.46e-05	0.00027	CcSEcCtD
Imipramine—Vomiting—Mitoxantrone—prostate cancer	3.45e-05	0.000269	CcSEcCtD
Imipramine—Convulsion—Prednisone—prostate cancer	3.44e-05	0.000268	CcSEcCtD
Imipramine—Agranulocytosis—Doxorubicin—prostate cancer	3.43e-05	0.000268	CcSEcCtD
Imipramine—Hypertension—Prednisone—prostate cancer	3.42e-05	0.000267	CcSEcCtD
Imipramine—Rash—Mitoxantrone—prostate cancer	3.42e-05	0.000267	CcSEcCtD
Imipramine—Dermatitis—Mitoxantrone—prostate cancer	3.42e-05	0.000267	CcSEcCtD
Imipramine—Headache—Mitoxantrone—prostate cancer	3.4e-05	0.000266	CcSEcCtD
Imipramine—Insomnia—Docetaxel—prostate cancer	3.39e-05	0.000265	CcSEcCtD
Imipramine—Paraesthesia—Docetaxel—prostate cancer	3.37e-05	0.000263	CcSEcCtD
Imipramine—Anxiety—Prednisone—prostate cancer	3.36e-05	0.000263	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.35e-05	0.000262	CcSEcCtD
Imipramine—Somnolence—Docetaxel—prostate cancer	3.34e-05	0.00026	CcSEcCtD
Imipramine—Discomfort—Prednisone—prostate cancer	3.34e-05	0.00026	CcSEcCtD
Imipramine—Eye disorder—Epirubicin—prostate cancer	3.33e-05	0.00026	CcSEcCtD
Imipramine—Tinnitus—Epirubicin—prostate cancer	3.32e-05	0.000259	CcSEcCtD
Imipramine—Desipramine—ADRB2—prostate cancer	3.31e-05	0.0118	CrCbGaD
Imipramine—Flushing—Epirubicin—prostate cancer	3.31e-05	0.000258	CcSEcCtD
Imipramine—Cardiac disorder—Epirubicin—prostate cancer	3.31e-05	0.000258	CcSEcCtD
Imipramine—Dyspepsia—Docetaxel—prostate cancer	3.3e-05	0.000258	CcSEcCtD
Imipramine—Hepatitis—Doxorubicin—prostate cancer	3.3e-05	0.000257	CcSEcCtD
Imipramine—Insomnia—Capecitabine—prostate cancer	3.29e-05	0.000257	CcSEcCtD
Imipramine—Hypoaesthesia—Doxorubicin—prostate cancer	3.28e-05	0.000256	CcSEcCtD
Imipramine—Paraesthesia—Capecitabine—prostate cancer	3.26e-05	0.000255	CcSEcCtD
Imipramine—Trimipramine—CYP2C19—prostate cancer	3.26e-05	0.0116	CrCbGaD
Imipramine—Decreased appetite—Docetaxel—prostate cancer	3.26e-05	0.000255	CcSEcCtD
Imipramine—Urinary tract disorder—Doxorubicin—prostate cancer	3.26e-05	0.000254	CcSEcCtD
Imipramine—Gastrointestinal disorder—Docetaxel—prostate cancer	3.24e-05	0.000253	CcSEcCtD
Imipramine—Asthenia—Etoposide—prostate cancer	3.24e-05	0.000253	CcSEcCtD
Imipramine—Anaphylactic shock—Prednisone—prostate cancer	3.24e-05	0.000253	CcSEcCtD
Imipramine—Oedema—Prednisone—prostate cancer	3.24e-05	0.000253	CcSEcCtD
Imipramine—Fatigue—Docetaxel—prostate cancer	3.24e-05	0.000253	CcSEcCtD
Imipramine—Angiopathy—Epirubicin—prostate cancer	3.23e-05	0.000252	CcSEcCtD
Imipramine—Urethral disorder—Doxorubicin—prostate cancer	3.23e-05	0.000252	CcSEcCtD
Imipramine—Nausea—Mitoxantrone—prostate cancer	3.22e-05	0.000252	CcSEcCtD
Imipramine—Methotrimeprazine—CYP2E1—prostate cancer	3.22e-05	0.0114	CrCbGaD
Imipramine—Immune system disorder—Epirubicin—prostate cancer	3.22e-05	0.000251	CcSEcCtD
Imipramine—Infection—Prednisone—prostate cancer	3.22e-05	0.000251	CcSEcCtD
Imipramine—Mediastinal disorder—Epirubicin—prostate cancer	3.21e-05	0.000251	CcSEcCtD
Imipramine—Constipation—Docetaxel—prostate cancer	3.21e-05	0.000251	CcSEcCtD
Imipramine—Diphenhydramine—CYP2C19—prostate cancer	3.2e-05	0.0114	CrCbGaD
Imipramine—Dyspepsia—Capecitabine—prostate cancer	3.2e-05	0.00025	CcSEcCtD
Imipramine—Pruritus—Etoposide—prostate cancer	3.19e-05	0.000249	CcSEcCtD
Imipramine—Shock—Prednisone—prostate cancer	3.18e-05	0.000249	CcSEcCtD
Imipramine—Arrhythmia—Epirubicin—prostate cancer	3.18e-05	0.000248	CcSEcCtD
Imipramine—Nervous system disorder—Prednisone—prostate cancer	3.17e-05	0.000248	CcSEcCtD
Imipramine—Tachycardia—Prednisone—prostate cancer	3.16e-05	0.000247	CcSEcCtD
Imipramine—Decreased appetite—Capecitabine—prostate cancer	3.16e-05	0.000247	CcSEcCtD
Imipramine—Alopecia—Epirubicin—prostate cancer	3.15e-05	0.000246	CcSEcCtD
Imipramine—Skin disorder—Prednisone—prostate cancer	3.14e-05	0.000245	CcSEcCtD
Imipramine—Gastrointestinal disorder—Capecitabine—prostate cancer	3.14e-05	0.000245	CcSEcCtD
Imipramine—Fatigue—Capecitabine—prostate cancer	3.13e-05	0.000245	CcSEcCtD
Imipramine—Hyperhidrosis—Prednisone—prostate cancer	3.13e-05	0.000244	CcSEcCtD
Imipramine—Mental disorder—Epirubicin—prostate cancer	3.12e-05	0.000244	CcSEcCtD
Imipramine—Doxepin—CYP2C19—prostate cancer	3.11e-05	0.011	CrCbGaD
Imipramine—Constipation—Capecitabine—prostate cancer	3.11e-05	0.000243	CcSEcCtD
Imipramine—Malnutrition—Epirubicin—prostate cancer	3.1e-05	0.000242	CcSEcCtD
Imipramine—Feeling abnormal—Docetaxel—prostate cancer	3.09e-05	0.000241	CcSEcCtD
Imipramine—Diarrhoea—Etoposide—prostate cancer	3.09e-05	0.000241	CcSEcCtD
Imipramine—Anorexia—Prednisone—prostate cancer	3.09e-05	0.000241	CcSEcCtD
Imipramine—Eye disorder—Doxorubicin—prostate cancer	3.08e-05	0.000241	CcSEcCtD
Imipramine—Tinnitus—Doxorubicin—prostate cancer	3.07e-05	0.00024	CcSEcCtD
Imipramine—Gastrointestinal pain—Docetaxel—prostate cancer	3.07e-05	0.00024	CcSEcCtD
Imipramine—Orphenadrine—CYP2E1—prostate cancer	3.06e-05	0.0109	CrCbGaD
Imipramine—Cardiac disorder—Doxorubicin—prostate cancer	3.06e-05	0.000239	CcSEcCtD
Imipramine—Flushing—Doxorubicin—prostate cancer	3.06e-05	0.000239	CcSEcCtD
Imipramine—Tension—Epirubicin—prostate cancer	3.04e-05	0.000238	CcSEcCtD
Imipramine—Dysgeusia—Epirubicin—prostate cancer	3.04e-05	0.000237	CcSEcCtD
Imipramine—Nervousness—Epirubicin—prostate cancer	3.01e-05	0.000235	CcSEcCtD
Imipramine—Feeling abnormal—Capecitabine—prostate cancer	2.99e-05	0.000234	CcSEcCtD
Imipramine—Angiopathy—Doxorubicin—prostate cancer	2.99e-05	0.000234	CcSEcCtD
Imipramine—Dizziness—Etoposide—prostate cancer	2.99e-05	0.000233	CcSEcCtD
Imipramine—Immune system disorder—Doxorubicin—prostate cancer	2.98e-05	0.000232	CcSEcCtD
Imipramine—Gastrointestinal pain—Capecitabine—prostate cancer	2.97e-05	0.000232	CcSEcCtD
Imipramine—Mediastinal disorder—Doxorubicin—prostate cancer	2.97e-05	0.000232	CcSEcCtD
Imipramine—Abdominal pain—Docetaxel—prostate cancer	2.97e-05	0.000232	CcSEcCtD
Imipramine—Body temperature increased—Docetaxel—prostate cancer	2.97e-05	0.000232	CcSEcCtD
Imipramine—Arrhythmia—Doxorubicin—prostate cancer	2.94e-05	0.00023	CcSEcCtD
Imipramine—Insomnia—Prednisone—prostate cancer	2.93e-05	0.000229	CcSEcCtD
Imipramine—Vision blurred—Epirubicin—prostate cancer	2.92e-05	0.000228	CcSEcCtD
Imipramine—Alopecia—Doxorubicin—prostate cancer	2.91e-05	0.000227	CcSEcCtD
Imipramine—Paraesthesia—Prednisone—prostate cancer	2.91e-05	0.000227	CcSEcCtD
Imipramine—Mental disorder—Doxorubicin—prostate cancer	2.89e-05	0.000225	CcSEcCtD
Imipramine—Urticaria—Capecitabine—prostate cancer	2.89e-05	0.000225	CcSEcCtD
Imipramine—Desipramine—CYP2E1—prostate cancer	2.88e-05	0.0102	CrCbGaD
Imipramine—Ill-defined disorder—Epirubicin—prostate cancer	2.88e-05	0.000225	CcSEcCtD
Imipramine—Body temperature increased—Capecitabine—prostate cancer	2.87e-05	0.000224	CcSEcCtD
Imipramine—Abdominal pain—Capecitabine—prostate cancer	2.87e-05	0.000224	CcSEcCtD
Imipramine—Vomiting—Etoposide—prostate cancer	2.87e-05	0.000224	CcSEcCtD
Imipramine—Malnutrition—Doxorubicin—prostate cancer	2.87e-05	0.000224	CcSEcCtD
Imipramine—Desipramine—CYP2C19—prostate cancer	2.85e-05	0.0101	CrCbGaD
Imipramine—Pipotiazine—CYP3A4—prostate cancer	2.85e-05	0.0101	CrCbGaD
Imipramine—Agitation—Epirubicin—prostate cancer	2.85e-05	0.000223	CcSEcCtD
Imipramine—Dyspepsia—Prednisone—prostate cancer	2.85e-05	0.000222	CcSEcCtD
Imipramine—Rash—Etoposide—prostate cancer	2.85e-05	0.000222	CcSEcCtD
Imipramine—Dermatitis—Etoposide—prostate cancer	2.84e-05	0.000222	CcSEcCtD
Imipramine—Headache—Etoposide—prostate cancer	2.83e-05	0.000221	CcSEcCtD
Imipramine—Tension—Doxorubicin—prostate cancer	2.82e-05	0.00022	CcSEcCtD
Imipramine—Decreased appetite—Prednisone—prostate cancer	2.81e-05	0.00022	CcSEcCtD
Imipramine—Dysgeusia—Doxorubicin—prostate cancer	2.81e-05	0.000219	CcSEcCtD
Imipramine—Malaise—Epirubicin—prostate cancer	2.8e-05	0.000218	CcSEcCtD
Imipramine—Fatigue—Prednisone—prostate cancer	2.79e-05	0.000218	CcSEcCtD
Imipramine—Nervousness—Doxorubicin—prostate cancer	2.79e-05	0.000218	CcSEcCtD
Imipramine—Syncope—Epirubicin—prostate cancer	2.78e-05	0.000217	CcSEcCtD
Imipramine—Leukopenia—Epirubicin—prostate cancer	2.78e-05	0.000217	CcSEcCtD
Imipramine—Constipation—Prednisone—prostate cancer	2.77e-05	0.000216	CcSEcCtD
Imipramine—Promazine—CYP2C19—prostate cancer	2.76e-05	0.00981	CrCbGaD
Imipramine—Palpitations—Epirubicin—prostate cancer	2.74e-05	0.000214	CcSEcCtD
Imipramine—Prochlorperazine—CYP3A4—prostate cancer	2.73e-05	0.00968	CrCbGaD
Imipramine—Loss of consciousness—Epirubicin—prostate cancer	2.73e-05	0.000213	CcSEcCtD
Imipramine—Vision blurred—Doxorubicin—prostate cancer	2.7e-05	0.000211	CcSEcCtD
Imipramine—Asthenia—Docetaxel—prostate cancer	2.69e-05	0.00021	CcSEcCtD
Imipramine—Convulsion—Epirubicin—prostate cancer	2.69e-05	0.00021	CcSEcCtD
Imipramine—Nausea—Etoposide—prostate cancer	2.68e-05	0.000209	CcSEcCtD
Imipramine—Hypertension—Epirubicin—prostate cancer	2.68e-05	0.000209	CcSEcCtD
Imipramine—Carbamazepine—CYP3A4—prostate cancer	2.68e-05	0.0095	CrCbGaD
Imipramine—Feeling abnormal—Prednisone—prostate cancer	2.67e-05	0.000208	CcSEcCtD
Imipramine—Ill-defined disorder—Doxorubicin—prostate cancer	2.66e-05	0.000208	CcSEcCtD
Imipramine—Pruritus—Docetaxel—prostate cancer	2.66e-05	0.000207	CcSEcCtD
Imipramine—Gastrointestinal pain—Prednisone—prostate cancer	2.65e-05	0.000207	CcSEcCtD
Imipramine—Agitation—Doxorubicin—prostate cancer	2.64e-05	0.000206	CcSEcCtD
Imipramine—Anxiety—Epirubicin—prostate cancer	2.63e-05	0.000205	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.62e-05	0.000205	CcSEcCtD
Imipramine—Discomfort—Epirubicin—prostate cancer	2.61e-05	0.000204	CcSEcCtD
Imipramine—Asthenia—Capecitabine—prostate cancer	2.61e-05	0.000204	CcSEcCtD
Imipramine—Malaise—Doxorubicin—prostate cancer	2.59e-05	0.000202	CcSEcCtD
Imipramine—Dry mouth—Epirubicin—prostate cancer	2.58e-05	0.000202	CcSEcCtD
Imipramine—Syncope—Doxorubicin—prostate cancer	2.57e-05	0.000201	CcSEcCtD
Imipramine—Urticaria—Prednisone—prostate cancer	2.57e-05	0.000201	CcSEcCtD
Imipramine—Pruritus—Capecitabine—prostate cancer	2.57e-05	0.000201	CcSEcCtD
Imipramine—Leukopenia—Doxorubicin—prostate cancer	2.57e-05	0.000201	CcSEcCtD
Imipramine—Diarrhoea—Docetaxel—prostate cancer	2.57e-05	0.0002	CcSEcCtD
Imipramine—Abdominal pain—Prednisone—prostate cancer	2.56e-05	0.0002	CcSEcCtD
Imipramine—Body temperature increased—Prednisone—prostate cancer	2.56e-05	0.0002	CcSEcCtD
Imipramine—Confusional state—Epirubicin—prostate cancer	2.55e-05	0.000199	CcSEcCtD
Imipramine—Palpitations—Doxorubicin—prostate cancer	2.54e-05	0.000198	CcSEcCtD
Imipramine—Oedema—Epirubicin—prostate cancer	2.53e-05	0.000198	CcSEcCtD
Imipramine—Anaphylactic shock—Epirubicin—prostate cancer	2.53e-05	0.000198	CcSEcCtD
Imipramine—Loss of consciousness—Doxorubicin—prostate cancer	2.52e-05	0.000197	CcSEcCtD
Imipramine—Infection—Epirubicin—prostate cancer	2.51e-05	0.000196	CcSEcCtD
Imipramine—Shock—Epirubicin—prostate cancer	2.49e-05	0.000194	CcSEcCtD
Imipramine—Convulsion—Doxorubicin—prostate cancer	2.49e-05	0.000194	CcSEcCtD
Imipramine—Diarrhoea—Capecitabine—prostate cancer	2.49e-05	0.000194	CcSEcCtD
Imipramine—Nervous system disorder—Epirubicin—prostate cancer	2.48e-05	0.000194	CcSEcCtD
Imipramine—Dizziness—Docetaxel—prostate cancer	2.48e-05	0.000194	CcSEcCtD
Imipramine—Thrombocytopenia—Epirubicin—prostate cancer	2.48e-05	0.000193	CcSEcCtD
Imipramine—Hypertension—Doxorubicin—prostate cancer	2.48e-05	0.000193	CcSEcCtD
Imipramine—Tachycardia—Epirubicin—prostate cancer	2.47e-05	0.000193	CcSEcCtD
Imipramine—Mianserin—CYP3A4—prostate cancer	2.47e-05	0.00875	CrCbGaD
Imipramine—Skin disorder—Epirubicin—prostate cancer	2.46e-05	0.000192	CcSEcCtD
Imipramine—Chlorpromazine—CYP2E1—prostate cancer	2.46e-05	0.00872	CrCbGaD
Imipramine—Hyperhidrosis—Epirubicin—prostate cancer	2.45e-05	0.000191	CcSEcCtD
Imipramine—Anxiety—Doxorubicin—prostate cancer	2.43e-05	0.00019	CcSEcCtD
Imipramine—Amitriptyline—CYP2E1—prostate cancer	2.43e-05	0.00862	CrCbGaD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.43e-05	0.000189	CcSEcCtD
Imipramine—Discomfort—Doxorubicin—prostate cancer	2.41e-05	0.000188	CcSEcCtD
Imipramine—Anorexia—Epirubicin—prostate cancer	2.41e-05	0.000188	CcSEcCtD
Imipramine—Amitriptyline—CYP2C19—prostate cancer	2.4e-05	0.00854	CrCbGaD
Imipramine—Dizziness—Capecitabine—prostate cancer	2.4e-05	0.000188	CcSEcCtD
Imipramine—Dry mouth—Doxorubicin—prostate cancer	2.39e-05	0.000187	CcSEcCtD
Imipramine—Vomiting—Docetaxel—prostate cancer	2.39e-05	0.000186	CcSEcCtD
Imipramine—Rash—Docetaxel—prostate cancer	2.37e-05	0.000185	CcSEcCtD
Imipramine—Dermatitis—Docetaxel—prostate cancer	2.36e-05	0.000185	CcSEcCtD
Imipramine—Confusional state—Doxorubicin—prostate cancer	2.36e-05	0.000184	CcSEcCtD
Imipramine—Headache—Docetaxel—prostate cancer	2.35e-05	0.000184	CcSEcCtD
Imipramine—Oedema—Doxorubicin—prostate cancer	2.34e-05	0.000183	CcSEcCtD
Imipramine—Anaphylactic shock—Doxorubicin—prostate cancer	2.34e-05	0.000183	CcSEcCtD
Imipramine—Infection—Doxorubicin—prostate cancer	2.33e-05	0.000182	CcSEcCtD
Imipramine—Asthenia—Prednisone—prostate cancer	2.32e-05	0.000181	CcSEcCtD
Imipramine—Vomiting—Capecitabine—prostate cancer	2.31e-05	0.00018	CcSEcCtD
Imipramine—Shock—Doxorubicin—prostate cancer	2.3e-05	0.00018	CcSEcCtD
Imipramine—Nervous system disorder—Doxorubicin—prostate cancer	2.3e-05	0.000179	CcSEcCtD
Imipramine—Thrombocytopenia—Doxorubicin—prostate cancer	2.29e-05	0.000179	CcSEcCtD
Imipramine—Rash—Capecitabine—prostate cancer	2.29e-05	0.000179	CcSEcCtD
Imipramine—Pruritus—Prednisone—prostate cancer	2.29e-05	0.000179	CcSEcCtD
Imipramine—Insomnia—Epirubicin—prostate cancer	2.29e-05	0.000179	CcSEcCtD
Imipramine—Dermatitis—Capecitabine—prostate cancer	2.29e-05	0.000179	CcSEcCtD
Imipramine—Tachycardia—Doxorubicin—prostate cancer	2.29e-05	0.000178	CcSEcCtD
Imipramine—Headache—Capecitabine—prostate cancer	2.28e-05	0.000178	CcSEcCtD
Imipramine—Skin disorder—Doxorubicin—prostate cancer	2.27e-05	0.000178	CcSEcCtD
Imipramine—Paraesthesia—Epirubicin—prostate cancer	2.27e-05	0.000177	CcSEcCtD
Imipramine—Hyperhidrosis—Doxorubicin—prostate cancer	2.26e-05	0.000177	CcSEcCtD
Imipramine—Clomipramine—CYP3A4—prostate cancer	2.25e-05	0.00801	CrCbGaD
Imipramine—Somnolence—Epirubicin—prostate cancer	2.25e-05	0.000176	CcSEcCtD
Imipramine—Anorexia—Doxorubicin—prostate cancer	2.23e-05	0.000174	CcSEcCtD
Imipramine—Nausea—Docetaxel—prostate cancer	2.23e-05	0.000174	CcSEcCtD
Imipramine—Dyspepsia—Epirubicin—prostate cancer	2.23e-05	0.000174	CcSEcCtD
Imipramine—Diarrhoea—Prednisone—prostate cancer	2.21e-05	0.000173	CcSEcCtD
Imipramine—Nortriptyline—CYP3A4—prostate cancer	2.2e-05	0.00782	CrCbGaD
Imipramine—Decreased appetite—Epirubicin—prostate cancer	2.2e-05	0.000172	CcSEcCtD
Imipramine—Gastrointestinal disorder—Epirubicin—prostate cancer	2.19e-05	0.000171	CcSEcCtD
Imipramine—Fatigue—Epirubicin—prostate cancer	2.18e-05	0.00017	CcSEcCtD
Imipramine—Constipation—Epirubicin—prostate cancer	2.16e-05	0.000169	CcSEcCtD
Imipramine—Nausea—Capecitabine—prostate cancer	2.16e-05	0.000169	CcSEcCtD
Imipramine—Dizziness—Prednisone—prostate cancer	2.14e-05	0.000167	CcSEcCtD
Imipramine—Insomnia—Doxorubicin—prostate cancer	2.12e-05	0.000165	CcSEcCtD
Imipramine—Paraesthesia—Doxorubicin—prostate cancer	2.1e-05	0.000164	CcSEcCtD
Imipramine—Feeling abnormal—Epirubicin—prostate cancer	2.09e-05	0.000163	CcSEcCtD
Imipramine—Somnolence—Doxorubicin—prostate cancer	2.08e-05	0.000163	CcSEcCtD
Imipramine—Trimipramine—CYP3A4—prostate cancer	2.07e-05	0.00737	CrCbGaD
Imipramine—Gastrointestinal pain—Epirubicin—prostate cancer	2.07e-05	0.000162	CcSEcCtD
Imipramine—Dyspepsia—Doxorubicin—prostate cancer	2.06e-05	0.000161	CcSEcCtD
Imipramine—Vomiting—Prednisone—prostate cancer	2.06e-05	0.000161	CcSEcCtD
Imipramine—Rash—Prednisone—prostate cancer	2.04e-05	0.000159	CcSEcCtD
Imipramine—Dermatitis—Prednisone—prostate cancer	2.04e-05	0.000159	CcSEcCtD
Imipramine—Decreased appetite—Doxorubicin—prostate cancer	2.04e-05	0.000159	CcSEcCtD
Imipramine—Headache—Prednisone—prostate cancer	2.03e-05	0.000158	CcSEcCtD
Imipramine—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.02e-05	0.000158	CcSEcCtD
Imipramine—Fatigue—Doxorubicin—prostate cancer	2.02e-05	0.000158	CcSEcCtD
Imipramine—Urticaria—Epirubicin—prostate cancer	2.01e-05	0.000157	CcSEcCtD
Imipramine—Constipation—Doxorubicin—prostate cancer	2e-05	0.000156	CcSEcCtD
Imipramine—Abdominal pain—Epirubicin—prostate cancer	2e-05	0.000156	CcSEcCtD
Imipramine—Body temperature increased—Epirubicin—prostate cancer	2e-05	0.000156	CcSEcCtD
Imipramine—Doxepin—CYP3A4—prostate cancer	1.98e-05	0.00702	CrCbGaD
Imipramine—Feeling abnormal—Doxorubicin—prostate cancer	1.93e-05	0.000151	CcSEcCtD
Imipramine—Orphenadrine—CYP3A4—prostate cancer	1.93e-05	0.00684	CrCbGaD
Imipramine—Nausea—Prednisone—prostate cancer	1.92e-05	0.00015	CcSEcCtD
Imipramine—Gastrointestinal pain—Doxorubicin—prostate cancer	1.92e-05	0.00015	CcSEcCtD
Imipramine—Urticaria—Doxorubicin—prostate cancer	1.86e-05	0.000145	CcSEcCtD
Imipramine—Abdominal pain—Doxorubicin—prostate cancer	1.85e-05	0.000145	CcSEcCtD
Imipramine—Body temperature increased—Doxorubicin—prostate cancer	1.85e-05	0.000145	CcSEcCtD
Imipramine—Asthenia—Epirubicin—prostate cancer	1.82e-05	0.000142	CcSEcCtD
Imipramine—Desipramine—CYP3A4—prostate cancer	1.81e-05	0.00644	CrCbGaD
Imipramine—Pruritus—Epirubicin—prostate cancer	1.79e-05	0.00014	CcSEcCtD
Imipramine—Promazine—CYP3A4—prostate cancer	1.76e-05	0.00624	CrCbGaD
Imipramine—Diarrhoea—Epirubicin—prostate cancer	1.73e-05	0.000135	CcSEcCtD
Imipramine—Asthenia—Doxorubicin—prostate cancer	1.68e-05	0.000131	CcSEcCtD
Imipramine—Dizziness—Epirubicin—prostate cancer	1.67e-05	0.000131	CcSEcCtD
Imipramine—Pruritus—Doxorubicin—prostate cancer	1.66e-05	0.000129	CcSEcCtD
Imipramine—Vomiting—Epirubicin—prostate cancer	1.61e-05	0.000126	CcSEcCtD
Imipramine—Diarrhoea—Doxorubicin—prostate cancer	1.6e-05	0.000125	CcSEcCtD
Imipramine—Rash—Epirubicin—prostate cancer	1.6e-05	0.000125	CcSEcCtD
Imipramine—Dermatitis—Epirubicin—prostate cancer	1.59e-05	0.000124	CcSEcCtD
Imipramine—Headache—Epirubicin—prostate cancer	1.59e-05	0.000124	CcSEcCtD
Imipramine—Dizziness—Doxorubicin—prostate cancer	1.55e-05	0.000121	CcSEcCtD
Imipramine—Chlorpromazine—CYP3A4—prostate cancer	1.55e-05	0.00549	CrCbGaD
Imipramine—Amitriptyline—CYP3A4—prostate cancer	1.53e-05	0.00543	CrCbGaD
Imipramine—Nausea—Epirubicin—prostate cancer	1.5e-05	0.000117	CcSEcCtD
Imipramine—Vomiting—Doxorubicin—prostate cancer	1.49e-05	0.000116	CcSEcCtD
Imipramine—Rash—Doxorubicin—prostate cancer	1.48e-05	0.000115	CcSEcCtD
Imipramine—Dermatitis—Doxorubicin—prostate cancer	1.48e-05	0.000115	CcSEcCtD
Imipramine—Headache—Doxorubicin—prostate cancer	1.47e-05	0.000115	CcSEcCtD
Imipramine—Nausea—Doxorubicin—prostate cancer	1.39e-05	0.000109	CcSEcCtD
Imipramine—CHRM4—Signaling Pathways—PIK3CA—prostate cancer	6.8e-07	6.97e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—VEGFA—prostate cancer	6.8e-07	6.96e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—IL6—prostate cancer	6.79e-07	6.95e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CCND1—prostate cancer	6.77e-07	6.94e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—IL6—prostate cancer	6.77e-07	6.93e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—STAT3—prostate cancer	6.77e-07	6.93e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CCND1—prostate cancer	6.76e-07	6.92e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—COMT—prostate cancer	6.74e-07	6.9e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CCND1—prostate cancer	6.74e-07	6.9e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—STAT3—prostate cancer	6.73e-07	6.89e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CCND1—prostate cancer	6.72e-07	6.88e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	6.71e-07	6.87e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GSTP1—prostate cancer	6.71e-07	6.87e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CTNNB1—prostate cancer	6.69e-07	6.85e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CD—prostate cancer	6.69e-07	6.85e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—SRC—prostate cancer	6.68e-07	6.84e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MMP9—prostate cancer	6.68e-07	6.84e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	6.67e-07	6.83e-06	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTEN—prostate cancer	6.67e-07	6.83e-06	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—KRAS—prostate cancer	6.67e-07	6.83e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CDKN1A—prostate cancer	6.66e-07	6.82e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	6.65e-07	6.81e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CCND1—prostate cancer	6.65e-07	6.81e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PTEN—prostate cancer	6.64e-07	6.8e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CCND1—prostate cancer	6.63e-07	6.79e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—INS—prostate cancer	6.63e-07	6.79e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ITPR1—prostate cancer	6.6e-07	6.76e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	6.59e-07	6.74e-06	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TP53—prostate cancer	6.58e-07	6.74e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MMP9—prostate cancer	6.58e-07	6.73e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	6.57e-07	6.73e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MMP9—prostate cancer	6.56e-07	6.72e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	6.55e-07	6.71e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MMP9—prostate cancer	6.54e-07	6.7e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CDKN1A—prostate cancer	6.54e-07	6.69e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PTEN—prostate cancer	6.54e-07	6.69e-06	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTEN—prostate cancer	6.53e-07	6.69e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CD—prostate cancer	6.53e-07	6.69e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PTEN—prostate cancer	6.52e-07	6.68e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MMP9—prostate cancer	6.52e-07	6.68e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	6.52e-07	6.67e-06	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—PIK3CA—prostate cancer	6.52e-07	6.67e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CAV1—prostate cancer	6.51e-07	6.67e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	6.51e-07	6.67e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PTEN—prostate cancer	6.5e-07	6.66e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	6.5e-07	6.65e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—CREBBP—prostate cancer	6.49e-07	6.65e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—AKT1—prostate cancer	6.48e-07	6.64e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PTEN—prostate cancer	6.48e-07	6.64e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MMP9—prostate cancer	6.46e-07	6.61e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—STAT3—prostate cancer	6.45e-07	6.6e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MMP9—prostate cancer	6.44e-07	6.59e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	6.43e-07	6.59e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PTEN—prostate cancer	6.42e-07	6.57e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	6.42e-07	6.57e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PTEN—prostate cancer	6.4e-07	6.55e-06	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—IL6—prostate cancer	6.39e-07	6.54e-06	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—IL6—prostate cancer	6.38e-07	6.53e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—AKT1—prostate cancer	6.38e-07	6.53e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—AKT1—prostate cancer	6.36e-07	6.52e-06	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PIK3CA—prostate cancer	6.36e-07	6.51e-06	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—EP300—prostate cancer	6.36e-07	6.51e-06	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PIK3CA—prostate cancer	6.35e-07	6.5e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—AKT1—prostate cancer	6.34e-07	6.5e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—EP300—prostate cancer	6.34e-07	6.49e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—AKT1—prostate cancer	6.32e-07	6.47e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—NOS3—prostate cancer	6.32e-07	6.47e-06	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TP53—prostate cancer	6.3e-07	6.45e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MYC—prostate cancer	6.29e-07	6.44e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TGFB1—prostate cancer	6.27e-07	6.42e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—AKT1—prostate cancer	6.26e-07	6.41e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MYC—prostate cancer	6.26e-07	6.41e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	6.25e-07	6.39e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TGFB1—prostate cancer	6.24e-07	6.39e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—TYMS—prostate cancer	6.24e-07	6.38e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—EP300—prostate cancer	6.24e-07	6.38e-06	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—EP300—prostate cancer	6.23e-07	6.38e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—EP300—prostate cancer	6.22e-07	6.37e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.22e-07	6.37e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—EP300—prostate cancer	6.2e-07	6.35e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—EP300—prostate cancer	6.18e-07	6.33e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—NOS3—prostate cancer	6.17e-07	6.31e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GSTM1—prostate cancer	6.16e-07	6.31e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—SRC—prostate cancer	6.16e-07	6.31e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CD—prostate cancer	6.15e-07	6.3e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—EGFR—prostate cancer	6.15e-07	6.3e-06	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	6.13e-07	6.27e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—EP300—prostate cancer	6.12e-07	6.27e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—EGFR—prostate cancer	6.12e-07	6.27e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—EP300—prostate cancer	6.11e-07	6.25e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—SRC—prostate cancer	6.06e-07	6.21e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—LPL—prostate cancer	6.05e-07	6.19e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—SRC—prostate cancer	6.05e-07	6.19e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—SRC—prostate cancer	6.03e-07	6.17e-06	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—IL6—prostate cancer	6.03e-07	6.17e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—SRC—prostate cancer	6.01e-07	6.16e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—VEGFA—prostate cancer	6e-07	6.14e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MYC—prostate cancer	5.99e-07	6.13e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	5.98e-07	6.12e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—SRC—prostate cancer	5.95e-07	6.1e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—STAT3—prostate cancer	5.94e-07	6.08e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—SRC—prostate cancer	5.94e-07	6.08e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CG—prostate cancer	5.93e-07	6.07e-06	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TP53—prostate cancer	5.93e-07	6.07e-06	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PIK3CA—prostate cancer	5.92e-07	6.06e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—VEGFA—prostate cancer	5.91e-07	6.05e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—VEGFA—prostate cancer	5.89e-07	6.03e-06	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—AKT1—prostate cancer	5.89e-07	6.03e-06	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—AKT1—prostate cancer	5.89e-07	6.03e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—VEGFA—prostate cancer	5.87e-07	6.01e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—EGFR—prostate cancer	5.86e-07	6e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—VEGFA—prostate cancer	5.86e-07	5.99e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—STAT3—prostate cancer	5.85e-07	5.99e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CYP1A1—prostate cancer	5.84e-07	5.98e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—STAT3—prostate cancer	5.83e-07	5.97e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CB—prostate cancer	5.83e-07	5.97e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—STAT3—prostate cancer	5.82e-07	5.95e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—NOS3—prostate cancer	5.81e-07	5.95e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—KRAS—prostate cancer	5.81e-07	5.95e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—VEGFA—prostate cancer	5.8e-07	5.94e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—STAT3—prostate cancer	5.8e-07	5.94e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ERCC2—prostate cancer	5.8e-07	5.93e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	5.78e-07	5.92e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—KRAS—prostate cancer	5.78e-07	5.92e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTGS2—prostate cancer	5.78e-07	5.92e-06	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—IL6—prostate cancer	5.77e-07	5.91e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—STAT3—prostate cancer	5.74e-07	5.88e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—STAT3—prostate cancer	5.73e-07	5.86e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CB—prostate cancer	5.69e-07	5.83e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTGS2—prostate cancer	5.64e-07	5.78e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—INS—prostate cancer	5.61e-07	5.75e-06	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—AKT1—prostate cancer	5.56e-07	5.69e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—KRAS—prostate cancer	5.53e-07	5.67e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MYC—prostate cancer	5.52e-07	5.65e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TGFB1—prostate cancer	5.51e-07	5.64e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CREBBP—prostate cancer	5.5e-07	5.63e-06	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PIK3CA—prostate cancer	5.47e-07	5.6e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—MTHFR—prostate cancer	5.45e-07	5.58e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MYC—prostate cancer	5.43e-07	5.56e-06	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IL6—prostate cancer	5.42e-07	5.55e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MYC—prostate cancer	5.42e-07	5.55e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TGFB1—prostate cancer	5.42e-07	5.55e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TGFB1—prostate cancer	5.41e-07	5.54e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MYC—prostate cancer	5.4e-07	5.53e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—EGFR—prostate cancer	5.4e-07	5.53e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TGFB1—prostate cancer	5.39e-07	5.52e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MYC—prostate cancer	5.39e-07	5.52e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TGFB1—prostate cancer	5.37e-07	5.5e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CB—prostate cancer	5.36e-07	5.49e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PPARA—prostate cancer	5.34e-07	5.47e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	5.34e-07	5.47e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MYC—prostate cancer	5.33e-07	5.46e-06	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—AKT1—prostate cancer	5.32e-07	5.45e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TGFB1—prostate cancer	5.32e-07	5.45e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MYC—prostate cancer	5.32e-07	5.45e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTGS2—prostate cancer	5.32e-07	5.44e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—EGFR—prostate cancer	5.31e-07	5.44e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	5.31e-07	5.44e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	5.31e-07	5.43e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—EGFR—prostate cancer	5.3e-07	5.43e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—EGFR—prostate cancer	5.29e-07	5.41e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—EGFR—prostate cancer	5.27e-07	5.39e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—EGFR—prostate cancer	5.22e-07	5.34e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CD—prostate cancer	5.21e-07	5.34e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—EGFR—prostate cancer	5.2e-07	5.33e-06	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—AKT1—prostate cancer	5.2e-07	5.32e-06	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—AKT1—prostate cancer	5.19e-07	5.31e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TP53—prostate cancer	5.17e-07	5.29e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TP53—prostate cancer	5.14e-07	5.26e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KRAS—prostate cancer	5.1e-07	5.22e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	5.08e-07	5.21e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTEN—prostate cancer	5.04e-07	5.16e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CAV1—prostate cancer	5.03e-07	5.14e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KRAS—prostate cancer	5.02e-07	5.14e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KRAS—prostate cancer	5.01e-07	5.13e-06	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—AKT1—prostate cancer	5e-07	5.12e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KRAS—prostate cancer	4.99e-07	5.11e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KRAS—prostate cancer	4.98e-07	5.1e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KRAS—prostate cancer	4.93e-07	5.05e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—NOS3—prostate cancer	4.92e-07	5.04e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTEN—prostate cancer	4.92e-07	5.04e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TP53—prostate cancer	4.92e-07	5.04e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KRAS—prostate cancer	4.92e-07	5.03e-06	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—AKT1—prostate cancer	4.84e-07	4.95e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—EP300—prostate cancer	4.81e-07	4.92e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IL6—prostate cancer	4.73e-07	4.84e-06	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PIK3CA—prostate cancer	4.71e-07	4.82e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IL6—prostate cancer	4.7e-07	4.82e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—EP300—prostate cancer	4.69e-07	4.8e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PIK3CA—prostate cancer	4.69e-07	4.8e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTEN—prostate cancer	4.64e-07	4.75e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	4.61e-07	4.72e-06	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PIK3CA—prostate cancer	4.61e-07	4.72e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PIK3CA—prostate cancer	4.6e-07	4.71e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	4.59e-07	4.7e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CG—prostate cancer	4.58e-07	4.69e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	4.57e-07	4.68e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CB—prostate cancer	4.54e-07	4.65e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TP53—prostate cancer	4.54e-07	4.64e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	4.53e-07	4.64e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	4.52e-07	4.62e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTGS2—prostate cancer	4.5e-07	4.61e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IL6—prostate cancer	4.5e-07	4.61e-06	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—AKT1—prostate cancer	4.47e-07	4.57e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TP53—prostate cancer	4.46e-07	4.57e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TP53—prostate cancer	4.45e-07	4.56e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TP53—prostate cancer	4.44e-07	4.54e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TP53—prostate cancer	4.42e-07	4.53e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—EP300—prostate cancer	4.42e-07	4.53e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TP53—prostate cancer	4.38e-07	4.49e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TP53—prostate cancer	4.37e-07	4.47e-06	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—AKT1—prostate cancer	4.36e-07	4.47e-06	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—AKT1—prostate cancer	4.34e-07	4.44e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—INS—prostate cancer	4.33e-07	4.44e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CREBBP—prostate cancer	4.24e-07	4.34e-06	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—AKT1—prostate cancer	4.15e-07	4.25e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IL6—prostate cancer	4.15e-07	4.25e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IL6—prostate cancer	4.08e-07	4.18e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IL6—prostate cancer	4.08e-07	4.17e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IL6—prostate cancer	4.06e-07	4.16e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IL6—prostate cancer	4.05e-07	4.15e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CD—prostate cancer	4.02e-07	4.12e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IL6—prostate cancer	4.01e-07	4.11e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IL6—prostate cancer	4e-07	4.09e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTEN—prostate cancer	3.93e-07	4.02e-06	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—AKT1—prostate cancer	3.84e-07	3.94e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—AKT1—prostate cancer	3.83e-07	3.92e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—NOS3—prostate cancer	3.8e-07	3.89e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—AKT1—prostate cancer	3.77e-07	3.86e-06	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—AKT1—prostate cancer	3.76e-07	3.85e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—AKT1—prostate cancer	3.76e-07	3.85e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—AKT1—prostate cancer	3.75e-07	3.84e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—EP300—prostate cancer	3.75e-07	3.83e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—AKT1—prostate cancer	3.74e-07	3.83e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—AKT1—prostate cancer	3.7e-07	3.79e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—AKT1—prostate cancer	3.69e-07	3.78e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CA—prostate cancer	3.56e-07	3.64e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CB—prostate cancer	3.51e-07	3.59e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTGS2—prostate cancer	3.48e-07	3.56e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CA—prostate cancer	3.47e-07	3.55e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CA—prostate cancer	3.27e-07	3.35e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTEN—prostate cancer	3.03e-07	3.1e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—AKT1—prostate cancer	2.9e-07	2.97e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—EP300—prostate cancer	2.89e-07	2.96e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—AKT1—prostate cancer	2.83e-07	2.9e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CA—prostate cancer	2.77e-07	2.84e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—AKT1—prostate cancer	2.67e-07	2.74e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—AKT1—prostate cancer	2.26e-07	2.32e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CA—prostate cancer	2.14e-07	2.19e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—AKT1—prostate cancer	1.75e-07	1.79e-06	CbGpPWpGaD
